FGFR2 and gastric cancer: However, all cases of GC exhibited positive PD-L1 expression regardless of whether FGFR2 genetic alterations were present (CPS, 1–10), suggesting that anti-PD-L1 therapy may be beneficial in the treatment of gastric cancer.